Low folate levels may be an atherogenic factor regardless of homocysteine levels in young healthy nonsmokers

Metabolism: Clinical and Experimental

Volumn 59, Issue 5, 2010, Pages 728-733

  Imamura, Akiko ^a   Murakami, Ryuichiro ^a   Takahashi, Ryotaro ^a   Cheng, Xian Wu ^a   Numaguchi, Yasushi ^a   Murohara, Toyoaki ^a   Okumura, Kenji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; ALLELE; ARTICLE; ATHEROGENESIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; ENDOTHELIUM; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ADULT; ATHEROSCLEROSIS; BLOOD GLUCOSE; BRACHIAL ARTERY; CHOLESTEROL; DNA; ENDOTHELIUM, VASCULAR; FOLIC ACID; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; INSULIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NITRIC OXIDE SYNTHASE TYPE III; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES; ULTRASONOGRAPHY, DOPPLER;

EID: 77950602692     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.09.017     Document Type: Article

References (33)

1. Yusuf S., Hawken S., and Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-942
2. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202-1206
3. Christensen B., Landaas S., and Stensvold I. Whole blood folate, homocysteine in serum, and risk of first acute myocardial infarction. Atherosclerosis 147 (1999) 317-326
4. Morrison H.I., Schaubel D., Desmeules M., and Wigle D.T. Serum folate and risk of fatal coronary heart disease. JAMA 275 (1996) 1893-1896
5. Kato T., Inoue T., Morooka T., Yoshimoto N., and Node K. Short-term passive smoking causes endothelial dysfunction via oxidative stress in nonsmokers. Can J Physiol Pharmacol 84 (2006) 523-529
6. Gabriel H.E., Crott J.W., Ghandour H., et al. Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults. Am J Clin Nutr 83 (2006) 835-841
7. Morita H., Taguchi J., and Kurihara H. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95 (1997) 2032-2036
8. Frosst P., Blom H.J., and Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
9. Al-Tahan J., Sola R., and Ruiz J.R. Methylenetetrahydrofolate reductase 677CT polymorphism and cobalamin, folate, and homocysteine status in Spanish adolescents. Ann Nutr Metab 52 (2008) 315-321
10. Brown K.S., Kluijtmans L.A., and Young I.S. Genetic evidence that nitric oxide modulates homocysteine: the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 23 (2003) 1014-1020
11. Araki A., and Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422 (1987) 43-52
12. Aso Y., Yamamoto R., and Wakabayashi S. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
13. Kosokabe T., Okumura K., and Sone T. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. Circulation 103 (2001) 2048-2054
14. Imamura A., Takahashi R., and Murakami R. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. Eur J Endocrinol 158 (2008) 189-195
15. Celermajer D.S., Sorensen K.E., and Gooch V.M. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
16. Mudd S.H., Finkelstein J.D., and Refsum H. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 20 (2000) 1704-1706
17. Dayal S., and Lentz S.R. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 28 (2008) 1596-1605
18. Mikael L.G., Genest Jr. J., and Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 98 (2006) 564-571
19. Verhaar M.C., Stroes E., and Rabelink T.J. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 22 (2002) 6-13
20. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
21. Chang P.Y., Lu S.C., and Lee C.M. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 102 (2008) 933-941
22. Bellamy M.F., McDowell I.F., and Ramsey M.W. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98 (1998) 1848-1852
23. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., and Celermajer D.S. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol 34 (1999) 2002-2006
24. Bellamy M.F., McDowell I.F., Ramsey M.W., Brownlee M., Newcombe R.G., and Lewis M.J. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 29 (1999) 659-662
25. Villa P., Perri C., and Suriano R. l-Folic acid supplementation in healthy postmenopausal women: effect on homocysteine and glycolipid metabolism. J Clin Endocrinol Metab 90 (2005) 4622-4629
26. Doshi S.N., and McDowell I.F. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105 (2002) 22-26
27. de Bree A., van Mierlo L.A., and Draijer R. Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 86 (2007) 610-617
28. Lonn E., Yusuf S., and Arnold M.J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
29. Bønaa K.H., Njølstad I., and Ueland P.M. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
30. Schnyder G., Roffi M., Flammer Y., Pin R., and Hess O.M. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288 (2002) 973-979
31. Jamison R.L., Hartigan P., and Kaufman J.S. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298 (2007) 1163-1170
32. Albert C.M., Cook N.R., and Gaziano J.M. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299 (2008) 2027-2036
33. Sawayama Y., Tatsukawa M., Maeda S., Ohnishi H., Furusyo N., and Hayashi J. Association of hyperhomocysteinemia and Chlamydia pneumoniae infection with carotid atherosclerosis and coronary artery disease in Japanese patients. J Infect Chemother 14 (2008) 232-237